CRL
Charles River Laboratories
NYSE: CRL · HEALTHCARE · DIAGNOSTICS & RESEARCH
$177.62
-2.23% today
Updated 2026-05-08
Market cap
$8.97B
P/E ratio
—
P/S ratio
2.23x
EPS (TTM)
$-2.91
Dividend yield
—
52W range
$133 – $229
Volume
0.9M
WallStSmart proprietary scores
39
out of 100
Grade: D
Sell
Investment rating
2.7
Growth
F4.8
Quality
C3.5
Profitability
D7.7
Valuation
B+3/9
Piotroski F-Score
Weak
1.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →195 stocks currently score above 75
Price targets
Analyst target
$199.33
+12.22%
12-Month target
—
—
Intrinsic (DCF)
$210.15
Margin of safety
+21.02%
1 Strong Buy10 Buy6 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ 21.02% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 1.68 — distress zone
- Thin margins at -3.60%
- Negative free cash flow $-14.83M
- Revenue declining -0.80% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $3.98B | $4.13B | $4.05B | $4.02B | $4.02B |
| Net income | $486.23M | $474.62M | $10.30M | $-144.34M | $-14.84M |
| EPS | — | — | — | — | $-2.91 |
| Free cash flow | $294.91M | $365.37M | $501.61M | $518.49M | $-14.83M |
| Profit margin | 12.23% | 11.49% | 0.25% | -3.59% | -3.60% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| — | ACKERMAN, THOMAS F | Sale | 16,000 | $31.35 |
| 2026-03-04 | GIRSHICK, BIRGIT | Sale | 328 | — |
| 2026-03-03 | LAPLUME, JOSEPH W | Buy | 25 | $174.54 |
Peer comparison
Smart narrative
Charles River Laboratories trades at $177.62. Our Smart Value Score of 39/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.68, it sits in the distress. TTM revenue stands at $4.02B. with profit margins at -3.60%. Our DCF model estimates intrinsic value at $210.15.
Frequently asked questions
What is Charles River Laboratories's stock price?
Charles River Laboratories (CRL) trades at $177.62.
Is Charles River Laboratories overvalued?
Smart Value Score 39/100 (Grade D, Sell). DCF value $210.15.
What is the price target of Charles River Laboratories (CRL)?
The analyst target price is $199.33, representing +12.2% upside from the current price of $177.62.
What is the intrinsic value of Charles River Laboratories (CRL)?
Based on our DCF model, intrinsic value is $210.15, a +21.0% margin of safety versus $177.62.
What is Charles River Laboratories's revenue?
TTM revenue is $4.02B.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
1.68 — distress.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.23x
ROE-4.23%
Beta1.45
50D MA$170.37
200D MA$176.34
Shares out0.05B
Float0.05B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—